Evolent Health Q2 revenue beats expectations

Overview

• US healthcare solutions firm's Q2 revenue rose and beat analyst expectations

• Company posted a net loss for Q2, but loss narrowed from prior year

• Full-year 2026 revenue guidance raised, adjusted EBITDA outlook tightened

Outlook

• Evolent raises 2026 revenue guidance to $2.6-$2.7 bln

• Company tightens 2026 Adjusted EBITDA guidance to $120-$135 mln

• Evolent expects 2027 revenue growth of over 25% versus 2026

Result Drivers

• SPECIALTY CARE DEMAND - Co said rising medical costs for health plans drove robust demand for its complex specialty care solutions, especially oncology

• NEW AND EXPANDED PARTNERSHIPS - Co highlighted new Oncology Performance Suite partnership and expanded Specialty Technology Services Suite contract as contributors to growth

• HIGHER MEDICAL COSTS - Co reported a higher medical expense ratio, reflecting increased medical costs relative to revenue

Company press release: ID:nPn3y0C76a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment technology peer group is "buy"

• Wall Street's median 12-month price target for Evolent Health, Inc. is $6.00, about 94.8% above its August 5 closing price of $3.08

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 17 three months ago

Reuters Recommended Reads

• Aug 5 - Agilon Health Q2 revenue beats estimates, raises outlook

• Aug 6 - Oscar Health beats Q2 revenue estimates, raises 2026 outlook

• Aug 5 - McKesson raises annual profit forecast on strong growth in specialty drug business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)